Physician profile
Daniel J Kuzio
NPI 1851475396
$3,457.30
in general payments reported to CMS, 2019-2025
36 companies · $21.44 in 2025
The $21.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $200 · 2022: $359 · 2023: $965 · 2024: $1,062 · 2025: $21.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $460.22 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $365.64 | 2019-2024 | |
| Novo Nordisk INC | $344.78 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $216.90 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $187.91 | 2022-2024 | |
| Noven Therapeutics, LLC | $178.42 | 2023-2024 | Xelstrym |
| Astellas Pharma US INC | $147.41 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $138.40 | 2019-2022 | |
| Exact Sciences Corporation | $125.62 | 2023-2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $113.10 | 2019-2024 | Xyosted |
| Aytu Biopharma, INC. | $111.13 | 2019 | |
| Idorsia Pharmaceuticals US INC | $101.71 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $99.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.30 | 2019-2024 | Jardiance |
| Amgen INC. | $80.04 | 2019-2024 | Repatha, Otezla |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $75.38 | 2019 | |
| Abbott Laboratories | $69.33 | 2022-2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $68.51 | 2019-2020 | |
| Neos Therapeutics, Lp | $65.51 | 2020-2024 | Adzenys Xr-Odt |
| Sanofi Pasteur INC. | $47.18 | 2019-2023 | |
| Tris Pharma INC | $40.64 | 2023 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.95 | 2024 | Xifaxan |
| Adlon Therapeutics L.P. | $30.07 | 2019-2020 | |
| Corium, LLC | $29.27 | 2024 | Azstarys |
| Shire North American Group INC | $28.77 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.09 | 2024 | Caplyta |
| Dynavax Technologies Corporation | $24.87 | 2023 | Heplisav-B |
| Almatica Pharma LLC | $24.31 | 2024 | Loreev Xr |
| Boston Scientific Corporation | $21.44 | 2025 | General - Pain Management |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.26 | 2022 | |
| Nevro Corp. | $19.36 | 2024 | Senza |
| Jazz Pharmaceuticals INC. | $18.30 | 2019 | |
| Halozyme INC | $17.02 | 2023 | |
| Tolmar, INC. | $16.06 | 2023 | |
| Esperion Therapeutics, INC. | $14.77 | 2022 | |
| Merck Sharp & Dohme LLC | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kuzio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.